

From: [MEDICINESMANAGEMENTPROJECTS \(NHS HUMBER AND NORTH YORKSHIRE INTEGRATED CARE BOARD\)](#)
Subject: Rybelsus® (oral semaglutide): risk of medication error due to introduction of a new formulation with increased bioavailability
Date: 16 September 2025 09:16:43

Dear Colleagues

-
Rybelsus® (oral semaglutide): risk of medication error due to introduction of a new formulation with increased bioavailability
-

Novo Nordisk announced very recently that Rybelsus® (oral semaglutide) 3mg, 7mg, 14mg tablets, will be replaced by a new formulation, which have an increased bioavailability, resulting in lower doses to attain the same drug exposure. The strength of the new tablets differs (1.5mg, 4mg, 9mg), and their bioequivalence is listed in the table below:

Initial formulation [one Oval tablet]	bioequivalent	new formulation [one round tablet]
3mg (starting dose)	=	1.5mg (starting dose)
7mg (maintenance dose)	=	4mg (maintenance dose)
14mg (maintenance dose)	=	9mg (maintenance dose)

The two formulations will temporarily co-exist on the market, which may lead to prescribing and dispensing errors, resulting in overdosing, and an increased risk of adverse events. The new formulation tablets will be available in the UK from yesterday - **15th of September** - and there may be a short delay as they are added to GP clinical systems.

We have made the decision at the HNY ICB, to categorise the new formulation as '**Do not prescribe – not yet classified**', which will give us more time to explore how to safely transition across, whilst minimising workload to GP practices. For now, please do not prescribe the new formulation. Our formulary will be updated accordingly.

Further information can be found at:

<https://www.medicines.org.uk/emc/dhpc/105215/Document#gref>

Information for people living with diabetes can be found:

<https://www.medicines.org.uk/emc/rmm/105214/Document>

We will send follow up information once we have more clarity around the timescales and impact on general practice. If you have any questions in the short term please contact:

- North Yorkshire and York: hnyicb-ny.rxline@nhs.net
- Hull and East Riding: hnyicb.prescribingqueries@nhs.net
- Northern Lincolnshire: hnyicb.moqueries@nhs.net

Many thanks

Pharmacy and Medicines Optimisation Team